Research Paper Volume 12, Issue 14 pp 14897—14917
Neuroprotective and neurogenic effects of novel tetramethylpyrazine derivative T-006 in Parkinson’s disease models through activating the MEF2-PGC1α and BDNF/CREB pathways
Figure 8. T-006 activates BDNF/CREB signaling pathway to provide neuro-repair in PD rats. Representative immunoblotting (A, C) and quantification of the relative protein level of p-CREB/CREB (B), BDNF (D) and synaptophysin (SYP, E) in the brain infarct region of sham, vehicle or T-006-treatment rats in 6-OHDA-induced PD rats. Data are expressed as mean±SEM (n=3 to 4 per group). ##P< 0.01 vs. sham group, and *P<0.05, **P<0.01, ***P<0.001 vs. 6-OHDA group.